Understanding the Half-Life Extension of Intravitreally Administered Antibodies Binding to Ocular Albumin.
albumin
half-life extension
ocular drug delivery
ocular pharmacokinetics
size exclusion chromatography
therapeutic proteins
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
26 Aug 2020
26 Aug 2020
Historique:
received:
10
07
2020
revised:
13
08
2020
accepted:
20
08
2020
entrez:
30
8
2020
pubmed:
30
8
2020
medline:
30
8
2020
Statut:
epublish
Résumé
The burden associated with frequent injections of current intravitreal (IVT) therapeutics may be reduced by long-acting delivery strategies. Binding to serum albumin has been shown to extend the ocular half-life in rabbits, however, the underlying molecular mechanisms and translational relevance remain unclear. The aim of this work was to characterize the in vitro and in vivo formation of complexes between human serum albumin (HSA) and an antigen-binding fragment of a rabbit antibody linked to an anti-HSA nanobody (FabA). The ocular and systemic pharmacokinetics of
Identifiants
pubmed: 32858986
pii: pharmaceutics12090810
doi: 10.3390/pharmaceutics12090810
pmc: PMC7559355
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
PLoS One. 2019 Jun 28;14(6):e0218613
pubmed: 31251757
Nat Commun. 2017 Mar 23;8:14837
pubmed: 28332616
Acta Ophthalmol Scand. 2007 Sep;85(6):618-22
pubmed: 17488318
Mol Pharm. 2016 Sep 6;13(9):2996-3003
pubmed: 27244474
Drug Des Devel Ther. 2013 Aug 05;7:711-22
pubmed: 23990705
Graefes Arch Clin Exp Ophthalmol. 1991;229(2):186-90
pubmed: 2044983
Graefes Arch Clin Exp Ophthalmol. 2019 Apr;257(4):741-748
pubmed: 30806775
J Ocul Pharmacol Ther. 2017 Mar;33(2):115-122
pubmed: 28055308
Eur J Pharm Biopharm. 2015 Sep;95(Pt B):215-26
pubmed: 25603198
Bioconjug Chem. 2019 Nov 20;30(11):2782-2789
pubmed: 31553572
Lancet Glob Health. 2017 Sep;5(9):e888-e897
pubmed: 28779882
Handb Exp Pharmacol. 2017;242:57-93
pubmed: 27783270
J Pharm Pharmacol. 1994 Mar;46(3):182-5
pubmed: 8027924
Horm Metab Res. 2001 May;33(5):312-6
pubmed: 11440279
Eye (Lond). 2011 Jun;25(6):661-72
pubmed: 21455242
Mol Pharm. 2020 Feb 3;17(2):695-709
pubmed: 31876425
Exp Eye Res. 2009 Mar;88(3):418-25
pubmed: 19000673
Exp Eye Res. 1983 Apr;36(4):493-503
pubmed: 6852130
Biotechnol Bioeng. 2001 Oct 20;75(2):233-8
pubmed: 11536147
J Control Release. 2019 Feb 28;296:140-149
pubmed: 30660630
J Cell Sci. 1980 Jun;43:319-28
pubmed: 7419623
Ophthalmology. 2019 Aug;126(8):1141-1154
pubmed: 30946888
J Control Release. 2010 Jan 4;141(1):2-12
pubmed: 19758573
Fortschr Ophthalmol. 1990;87(3):283-6
pubmed: 2376377
J Ophthalmol. 2012;2012:786870
pubmed: 22523653
Ophthalmol Retina. 2018 Jul;2(7):645-653
pubmed: 31047372
BMC Ophthalmol. 2016 Jan 16;16:11
pubmed: 26774505
Am J Ophthalmol. 1959 Jan;47(1 Pt 2):361-8
pubmed: 13617364
Invest Ophthalmol Vis Sci. 2000 Apr;41(5):961-4
pubmed: 10752928
Int J Ophthalmol. 2013 Apr 18;6(2):169-73
pubmed: 23638418
Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5390-400
pubmed: 26275136
Eur Biophys J. 2015 Jul;44(5):367-71
pubmed: 26003320
Ophthalmology. 2020 Jan;127(1):72-84
pubmed: 30986442
Nippon Ganka Gakkai Zasshi. 1984 Dec;88(12):1487-91
pubmed: 6442540
Transl Vis Sci Technol. 2019 Nov 01;8(6):1
pubmed: 31695962
Expert Rev Ophthalmol. 2010 Feb 1;5(1):75-93
pubmed: 20305803
Exp Eye Res. 2015 Aug;137:111-24
pubmed: 25975234
Biochim Biophys Acta. 1983 Jul 5;758(1):17-23
pubmed: 6860709
Biochim Biophys Acta. 2013 Dec;1830(12):5526-34
pubmed: 23639804
Drugs. 2019 Dec;79(18):1997-2000
pubmed: 31768932